Form D · Biotechnology

Knopp Biosciences LLC

Pittsburgh, PA · CIK 0001497598

Offering snapshot reported Jan 5, 2021 · SEC filing

Reported sold
$1
Offering amount: $1
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 21, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 5, 2021Initial$1No comparison1SEC filing
Oct 27, 2020Amendment$12,608,668$5,036,134vs Jul 7, 202024SEC filing
Jul 7, 2020Initial$7,572,534No comparison10SEC filing
Jun 19, 2020Amendment$14,942,729$4,692,729vs Feb 27, 201978SEC filing
Mar 5, 2020Initial$1,000,000No comparison1SEC filing
Mar 2, 2020Amendment$12,719,711-$2,223,018vs Jun 24, 201926SEC filing
Jun 24, 2019Amendment$14,942,729$4,692,729vs Feb 27, 201978SEC filing
Mar 1, 2019Amendment$10,250,000$0vs Feb 27, 20193SEC filing
Feb 27, 2019Initial$10,250,000No comparison3SEC filing
Jul 24, 2018Amendment$28,000,000$5,000,000vs Dec 5, 201761SEC filing
Jun 26, 2018Amendment$14,942,729-$8,057,271vs Dec 5, 201778SEC filing
Dec 5, 2017Amendment$23,000,000$8,057,271vs Jun 30, 201760SEC filing
Jun 30, 2017Amendment$14,942,729$0vs Jul 5, 201678SEC filing
Mar 2, 2017Amendment$17,449,297$2,506,568vs Jul 5, 201655SEC filing
Dec 28, 2016Amendment$17,154,649$2,211,920vs Jul 5, 201654SEC filing
Jul 5, 2016Amendment$14,942,729$0vs Jul 8, 201578SEC filing
May 25, 2016Amendment$12,499,813$0vs Feb 16, 201650SEC filing
Feb 16, 2016Amendment$12,499,813-$2,442,916vs Jul 8, 201550SEC filing
Jul 8, 2015Amendment$14,942,729$0vs Jul 14, 201478SEC filing
Apr 14, 2015Amendment$5,396,757$371,757vs Dec 11, 201420SEC filing
Dec 11, 2014Amendment$5,025,000$1,909,607vs May 28, 201418SEC filing
Jul 14, 2014Amendment$14,942,729$11,827,336vs May 28, 201478SEC filing
May 28, 2014Amendment$3,115,393No comparison10SEC filing
Apr 14, 2014InitialYet to sellNo comparison0SEC filing
Jul 18, 2013Amendment$14,942,729$0vs Nov 8, 201278SEC filing
Nov 8, 2012Amendment$14,942,729No comparison78SEC filing
Jul 9, 2012InitialYet to sellNo comparison0SEC filing
Sep 3, 2010Initial$140,000,000No comparison90SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-385230
The issuer issues profit interests ($0 initial value).

Source: Form D, filed Jan 5, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
C. David Adair Director
Michael E. Bozik Director, Executive, Promoter
Stephen E Butts Director
Steven Dworetzky Executive
Steve Dworetzky Executive
Benjamin A. Gomez Director
Valentin K. Gribkoff Executive
Gregory T. Hebrank Director, Executive, Promoter
Evan W. Ingersoll Executive
Suresh Khemani Executive
Shane Kovacs Director
Mark Kreston Executive
Frank J. Lucchino, Jr. Executive
James Mather Executive
Jeffrey S. Mc Cormick Director
Thomas V. Petzinger Jr. Director, Executive, Promoter
Thomas V. Petzinger, Jr. Director, Executive, Promoter
Calman Prussin Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2100 Wharton Street, Suite 615
Pittsburgh, PA, 15203